

## ASX Price Query

Melissa Kostopoulos  
Listing Compliance - Melbourne  
ASX Compliance Pty Ltd  
525 Collins Street  
North Tower Level 4  
MELBOURNE VIC 3000

Dear Melissa

### Rhythm Biosciences Limited (RHY) – ASX Aware Query

We refer to your letter of 12 October 2023 and provide the following responses to your questions:

1. *Is RHY aware of any information concerning it that has not been announced to the market which, if known by some in the market, could explain the recent trading in its securities?*

**Response:** No

2. *If the answer to question 1 is “no”, is there any other explanation that RHY may have for the recent trading in its securities?*

**Response:** The Company held its 2023 Annual General Meeting (AGM) on 10 October 2023 commencing at 11.00am and prior to that meeting the Company released to the ASX Market Announcements Platform its **2023 AGM Investor Presentation** which contained:

- an outline of the new in vitro diagnostic medical devices regulation standards (IVDR) which will replace the current in vitro diagnostic medical devices directive (IVDD) on May 2026 for Class C devices in the EU (initially outlined in the Appendix 4C on 31 July 2023);
- reference to the revised TGA guidance released in a June 2023 document which signaled its intention to adopt similarly stringent criteria consistent with these increased requirements for moving from the IVDD CE to an IVDR CE standard (initially outlined in the Appendix 4C on 31 July 2023);
- RHY's intention to submit its application to ensure compliance with the new standards (which will entail additional work) (initially outlined in the Appendix 4C on 31 July 2023);
- confirmation that our current regulatory approvals remain valid;
- disclosure of RHY's cash balance of \$1.6 million on 30 September 2023; and
- RHY's forecast material R&D tax refund which is expected in the short term (as discussed).

3. *Please confirm that RHY is complying with the Listing Rules and, in particular, Listing Rule 3.1.*

**Response:** Yes

**- ENDS -**

## Authorisation & Additional Information

This announcement was authorised by the Board of Directors of Rhythm Biosciences Limited.

For further information contact us via [investor@rhythmbio.com](mailto:investor@rhythmbio.com) or on +61 3 8256 2880:

<b>Mr Otto Buttula</b> Executive Chairman	<b>Mr Paul Smith</b> CFO & Joint Company Secretary	<b>Ms Andrea Steele</b> Joint Company Secretary
--	---	--

## About Rhythm Biosciences

Rhythm Biosciences Ltd (ASX: RHY) is an Australian innovative, medical diagnostics company aimed at delivering simple, affordable blood tests for accurate and early detection of cancers. Rhythm is focused on improving patient outcomes through detection at the earliest possible stage, reducing the global burden of cancer and saving lives.

Rhythm Biosciences is committed to working with likeminded global partners to achieve commercialisation and distribution of these simple solutions.

The company was founded in 2017 and is headquartered in Melbourne, Australia. For more information, visit [rhythmbio.com](http://rhythmbio.com) and follow the company on LinkedIn and Twitter.

## About ColoSTAT®

Colorectal cancer (CRC), also referred to as bowel cancer, is the second leading cause of cancer deaths globally. If diagnosed early, colorectal cancer is curable.

The ColoSTAT® Test-Kit is Rhythm Bioscience's simple blood test for the detection of CRC. It measures five specific protein biomarkers that indicate the likelihood presence of CRC. The test can be used as an alternative for individuals who are unable or unwilling to participate in current screening programs.

The ColoSTAT® Test-Kit is based on research from Australia's CSIRO and is patent protected internationally. It has the potential to play a key role in reducing the mortality rate and healthcare costs associated with colorectal cancer.



12 October 2023

Reference: 81978

Mr Paul Smith  
Company Secretary  
Rhythm Biosciences Limited  
Bio21 Institute, 30 Flemington Road  
Parkville, Vic 3010

By email: Paul.Smith@rhythmbio.com

Dear Mr Smith

**Rhythm Biosciences Limited ('RHY'): Price - Query**

ASX refers to the following:

- A. The change in the price of RHY's securities from a high of \$0.32 at close of trading on Monday 9 October 2023 to a low of \$0.20 today.
- B. The significant increase in the volume of RHY's securities traded today.

**Request for information**

In light of this, ASX asks RHY to respond separately to each of the following questions and requests for information:

- 1. Is RHY aware of any information concerning it that has not been announced to the market which, if known by some in the market, could explain the recent trading in its securities?

If the answer to question 1 is "yes".

- (a) Is RHY relying on Listing Rule 3.1A not to announce that information under Listing Rule 3.1? Please note that the recent trading in RHY's securities would suggest to ASX that such information may have ceased to be confidential and therefore RHY may no longer be able to rely on Listing Rule 3.1A. Accordingly, if the answer to this question is "yes", you need to contact us immediately to discuss the situation.
  - (b) Can an announcement be made immediately? Please note, if the answer to this question is "no", you need to contact us immediately to discuss requesting a trading halt (see below).
  - (c) If an announcement cannot be made immediately, why not and when is it expected that an announcement will be made?
- 2. If the answer to question 1 is "no", is there any other explanation that RHY may have for the recent trading in its securities?
- 3. Please confirm that RHY is complying with the Listing Rules and, in particular, Listing Rule 3.1.
- 4. Please confirm that RHY's responses to the questions above have been authorised and approved under its published continuous disclosure policy or otherwise by its board or an officer of RHY with delegated authority from the board to respond to ASX on disclosure matters.

---

### When and where to send your response

This request is made under Listing Rule 18.7. Your response is required as soon as reasonably possible and, in any event, by no later than **9:30 AM AEDT Friday, 13 October 2023**. You should note that if the information requested by this letter is information required to be given to ASX under Listing Rule 3.1 and it does not fall within the exceptions mentioned in Listing Rule 3.1A, RHY's obligation is to disclose the information 'immediately'. This may require the information to be disclosed before the deadline set out in the previous paragraph and may require RHY to request a trading halt immediately.

Your response should be sent to me by e-mail at [ListingsComplianceMelbourne@asx.com.au](mailto:ListingsComplianceMelbourne@asx.com.au). It should not be sent directly to the ASX Market Announcements Office. This is to allow me to review your response to confirm that it is in a form appropriate for release to the market, before it is published on the ASX Market Announcements Platform.

### Trading halt

If you are unable to respond to this letter by the time specified above, or if the answer to question 1 is "yes" and an announcement cannot be made immediately, you should discuss with us whether it is appropriate to request a trading halt in RHY's securities under Listing Rule 17.1. If you wish a trading halt, you must tell us:

- the reasons for the trading halt;
- how long you want the trading halt to last;
- the event you expect to happen that will end the trading halt;
- that you are not aware of any reason why the trading halt should not be granted; and
- any other information necessary to inform the market about the trading halt, or that we ask for.

We require the request for a trading halt to be in writing. The trading halt cannot extend past the commencement of normal trading on the second day after the day on which it is granted. You can find further information about trading halts in Guidance Note 16 *Trading Halts & Voluntary Suspensions*.

### Suspension

If you are unable to respond to this letter by the time specified above, ASX will likely suspend trading in RHY's securities under Listing Rule 17.3.

### Listing Rules 3.1 and 3.1A

In responding to this letter, you should have regard to RHY's obligations under Listing Rules 3.1 and 3.1A and also to Guidance Note 8 *Continuous Disclosure*: Listing Rules 3.1 – 3.1B. It should be noted that RHY's obligation to disclose information under Listing Rule 3.1 is not confined to, nor is it necessarily satisfied by, answering the questions set out in this letter.

### Release of correspondence between ASX and entity

ASX reserves the right to release all or any part of this letter, your reply and any other related correspondence between us to the market under Listing Rule 18.7A.

### Questions

If you have any questions in relation to the above, please do not hesitate to contact me.

---

Regards

---

**Melissa Kostopoulos**  
Senior Adviser, Listings Compliance